NCT06966401 - Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Biotech Hunter

Enrollment

600

Participants

Timeline

Start Date

April 16, 2025

Primary Completion Date

May 31, 2029

Study Completion Date

May 31, 2030

Conditions

Major Depressive Disorder

Interventions

DRUG

NBI-1065845

NBI-1065845 tablets

Trial Locations (18)

10461

RECRUITING

Neurocrine Clinical Site, The Bronx

10549

RECRUITING

Neurocrine Clinical Site, Mount Kisco

30318

RECRUITING

Neurocrine Clinical Site, Atlanta

33024

RECRUITING

Neurocrine Clinical Site, Hollywood

33607

RECRUITING

Neurocrine Clinical Site, Tampa

44012

RECRUITING

Neurocrine Clinical Site, Avon Lake

63304

RECRUITING

Neurocrine Clinical Site, Saint Charles

72204

RECRUITING

Neurocrine Clinical Site, Little Rock

75251

RECRUITING

Neurocrine Clinical Site, Dallas

77381

RECRUITING

Neurocrine Clinical Site, The Woodlands

77407

RECRUITING

Neurocrine Clinical Site, Richmond

90660

RECRUITING

Neurocrine Clinical Site, Pico Rivera

91786

RECRUITING

Neurocrine Clinical Site, Upland

92866

RECRUITING

Neurocrine Clinical Site, Orange

98201

RECRUITING

Neurocrine Clinical Site, Everett

32751-5669

RECRUITING

Neurocrine Clinical Site, Maitland

02116

RECRUITING

Neurocrine Clinical Site, Boston

02472

RECRUITING

Neurocrine Clinical Site, Watertown